On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

How could a non-opioid painkiller improve the lives of people with chronic pain? What makes a non-opioid painkiller safer than traditional opioids for pain management? Painkillers like opioids can ...

The FDA has approved suzetrigine, a groundbreaking painkiller that blocks sodium channels to provide opioid-level pain relief without the risks of addiction, sedation, or overdose. Known as ...

The success of new non-opioid drugs and other treatments for pain offer some relief for sufferers.

To get FDA approval, scientists must be able to demonstrate that a new drug or treatment is safe and effective. And currently, before they can test a new therapy in humans, they must show proof ...

According to the FDA, the recall was initiated March 26. The 189 cases of butter were sold in stores in Vermont, New York, Pennsylvania, Maine, Connecticut, New Hampshire, and Arkansas.

Minnesota is home to hundreds of medical device companies that can't sell new technologies or produce revenue without FDA review. A federal official did not answer questions about the cause of the ...

Layoffs at the Food and Drug Administration are expected to reduce the FDA's workforce by 20%. Susan Mayne, former director of the Center for Food Safety and Applied Nutrition at the FDA ...

U.S. Food and Drug Administration approvals of life-changing, high-risk medical devices reportedly slowed to a 10-year low for the January to March period, as recent layoffs have reportedly had ...

In this first installment of "Exit Interviews," MedPage Today editor-in-chief Jeremy Faust, MD, sits down with two-time FDA Commissioner Robert Califf, MD, to discuss what it was like running a ...